Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthopediatrics (KIDS) Total Debt (2016 - 2025)

Historic Total Debt for Orthopediatrics (KIDS) over the last 10 years, with Q3 2025 value amounting to $100.7 million.

  • Orthopediatrics' Total Debt rose 3768.9% to $100.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $100.7 million, marking a year-over-year increase of 3768.9%. This contributed to the annual value of $73.9 million for FY2024, which is 63412.52% up from last year.
  • As of Q3 2025, Orthopediatrics' Total Debt stood at $100.7 million, which was up 3768.9% from $97.8 million recorded in Q2 2025.
  • Over the past 5 years, Orthopediatrics' Total Debt peaked at $100.7 million during Q3 2025, and registered a low of $800000.0 during Q3 2023.
  • For the 5-year period, Orthopediatrics' Total Debt averaged around $25.8 million, with its median value being $1.1 million (2021).
  • Per our database at Business Quant, Orthopediatrics' Total Debt tumbled by 9738.56% in 2023 and then surged by 904225.0% in 2024.
  • Over the past 5 years, Orthopediatrics' Total Debt (Quarter) stood at $1.0 million in 2021, then decreased by 13.12% to $907000.0 in 2022, then skyrocketed by 1009.15% to $10.1 million in 2023, then soared by 634.13% to $73.9 million in 2024, then skyrocketed by 36.36% to $100.7 million in 2025.
  • Its Total Debt was $100.7 million in Q3 2025, compared to $97.8 million in Q2 2025 and $73.9 million in Q1 2025.